MXPA05004486A - Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular. - Google Patents
Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular.Info
- Publication number
- MXPA05004486A MXPA05004486A MXPA05004486A MXPA05004486A MXPA05004486A MX PA05004486 A MXPA05004486 A MX PA05004486A MX PA05004486 A MXPA05004486 A MX PA05004486A MX PA05004486 A MXPA05004486 A MX PA05004486A MX PA05004486 A MXPA05004486 A MX PA05004486A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- carbon atoms
- phenyl
- hydrogen
- selective cytokine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42290002P | 2002-10-31 | 2002-10-31 | |
PCT/US2003/034535 WO2004041181A2 (en) | 2002-10-31 | 2003-10-31 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05004486A true MXPA05004486A (es) | 2005-07-26 |
Family
ID=32312567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05004486A MXPA05004486A (es) | 2002-10-31 | 2003-10-31 | Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1567148A4 (ja) |
JP (1) | JP2006509743A (ja) |
KR (1) | KR20050062649A (ja) |
CN (1) | CN1731997A (ja) |
AU (1) | AU2003285107B2 (ja) |
BR (1) | BR0315889A (ja) |
CA (1) | CA2504263A1 (ja) |
MX (1) | MXPA05004486A (ja) |
NZ (1) | NZ540185A (ja) |
TW (1) | TW200418455A (ja) |
WO (1) | WO2004041181A2 (ja) |
ZA (1) | ZA200503468B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
EP2663549B1 (en) * | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
KR101908330B1 (ko) | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물 |
AU2019382044A1 (en) * | 2018-11-14 | 2021-06-03 | Zhuhai Qiwei Bio-Technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
EP3886852B1 (en) * | 2018-12-03 | 2024-01-31 | Smilebiotek Zhuhai Limited | Octyl gallate and esters thereof of for use in the treatment and prevention of age-related macular degeneration caused by bacillus megaterium |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577589A (en) * | 1897-02-23 | Valve for explosive-engines | ||
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
CN1265590A (zh) * | 1997-07-31 | 2000-09-06 | 赛尔金有限公司 | 取代的链烷异羟肟酸及降低肿瘤坏死因子α水平的方法 |
KR100699968B1 (ko) * | 1998-05-11 | 2007-03-28 | 더 칠드런스 메디칼 센터 코포레이션 | 2-프탈이미디노글루타르산 유사체 및 안기오게네시스억제제로서의 이의 용도 |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
JP2000159761A (ja) * | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
CN1646131A (zh) * | 2002-04-19 | 2005-07-27 | 史密丝克莱恩比彻姆公司 | 新化合物 |
EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
AU2003228509B2 (en) * | 2002-10-15 | 2008-06-26 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
-
2003
- 2003-10-31 AU AU2003285107A patent/AU2003285107B2/en not_active Ceased
- 2003-10-31 MX MXPA05004486A patent/MXPA05004486A/es active IP Right Grant
- 2003-10-31 CA CA002504263A patent/CA2504263A1/en not_active Abandoned
- 2003-10-31 ZA ZA200503468A patent/ZA200503468B/en unknown
- 2003-10-31 NZ NZ540185A patent/NZ540185A/en not_active IP Right Cessation
- 2003-10-31 KR KR1020057007608A patent/KR20050062649A/ko not_active Application Discontinuation
- 2003-10-31 EP EP03779423A patent/EP1567148A4/en not_active Withdrawn
- 2003-10-31 BR BR0315889-6A patent/BR0315889A/pt not_active IP Right Cessation
- 2003-10-31 CN CNA2003801080906A patent/CN1731997A/zh active Pending
- 2003-10-31 WO PCT/US2003/034535 patent/WO2004041181A2/en active Application Filing
- 2003-10-31 JP JP2004550274A patent/JP2006509743A/ja active Pending
- 2003-10-31 TW TW092130486A patent/TW200418455A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1567148A2 (en) | 2005-08-31 |
KR20050062649A (ko) | 2005-06-23 |
AU2003285107A1 (en) | 2004-06-07 |
AU2003285107B2 (en) | 2008-01-10 |
BR0315889A (pt) | 2005-10-04 |
TW200418455A (en) | 2004-10-01 |
CN1731997A (zh) | 2006-02-08 |
ZA200503468B (en) | 2006-10-25 |
WO2004041181A2 (en) | 2004-05-21 |
WO2004041181A3 (en) | 2005-02-17 |
JP2006509743A (ja) | 2006-03-23 |
EP1567148A4 (en) | 2010-09-15 |
NZ540185A (en) | 2008-01-31 |
CA2504263A1 (en) | 2004-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080213219A1 (en) | Methods for treatment and management of macular degeneration using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
ZA200503467B (en) | Composition for the treatment of macular degeneartion | |
US20110038832A1 (en) | Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | |
JP2006510606A (ja) | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 | |
MXPA05004486A (es) | Metodo de uso y composiciones que comprenden farmacos inhibidores de citocina, selectivos, para el tratamiento y el manejo de la degeneracion macular. | |
AU2008201418B2 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
US20080027113A1 (en) | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration | |
MXPA06004622A (en) | Cytokine inhibitory drugs for treatment of macular degeneration | |
MXPA06004627A (en) | Composition and method for treating macular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |